Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead combo drug fights all genotypes of hep C infection: data

[Reuters] – Gilead Sciences Inc said its experimental hepatitis C combination was effective against all genotypes of the viral infection, citing data from four late-stage studies. The trials were evaluating a once-daily, … . . . → Read More: Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead combo drug fights all genotypes of hep C infection: data Similar Articles: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment Market Update (NASDAQ:GILD): Gilead shares dip after warning about hepatitis C drug interaction